Sure! Here’s the translation into American English:
—
Owkin has introduced K Pro, an innovative co-pilot that integrates artificial intelligence in the field of biomedical research and pharmaceutical development. This platform aims to optimize decision-making in pharmaceutical and biotechnology companies during the drug discovery and development cycle, with the goal of increasing clinical success rates and accelerating the acquisition of biological insights that can transform the direction of their programs.
Developed from over ten years of advancements in artificial intelligence and in collaboration with renowned academic and industrial partners, K Pro is designed to serve both scientists and executives. Its interface allows interaction through natural language, making it simpler to formulate complex questions and obtain relevant clinical answers while integrating workflows that have traditionally been fragmented.
A key component of K Pro is its link to Owkin Zero, an optimized biological language model that outperforms other leading models on the market. The platform offers secure access to high-quality biomedical datasets and allows for the inclusion of private data, maximizing its analytical capacity.
Thomas Clozel, co-founder and CEO of Owkin, emphasized the significance of this innovation: “K Pro brings us closer to an intelligence that evolves with the complexity of biology, representing a key step towards our mission of achieving Superior Artificial Biological Intelligence.” This evolution aims not only for a more effective modeling of biology but also for the development of transformative therapies in a shorter time frame.
The initial results of K Pro are impressive, achieving a 70% acceleration in identifying drug targets, reducing the time required for this task from over a year to just three months. It has also enabled the generation of positioning strategies ready for presentation in hours instead of months, and facilitated the drafting of scientific reviews in various contexts.
The validity of Owkin’s approach has been corroborated through collaborations with leading pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, and Sanofi. Ben Mellows, CEO of Micregen, argued that using K Pro has been essential for effectively communicating their proposal to investors, condensing a vast amount of information in record time.
Owkin’s historical results demonstrate the tangible impact of its technology on clinical trials and discoveries in the realm of diseases, showcasing its capability to prevent futility and reduce the duration of clinical trials.
With a strong commitment to addressing the complexity of biology through AI, Owkin is on the path to building the first Biological Superintelligence, combining advanced biological language models with an analytical and innovative approach.
—
If you need further assistance or modifications, just let me know!
Source: MiMub in Spanish